Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

A high expression level of epidermal growth factor receptor (EGFR)/HER1 has been suggested to lead to a shorter survival time and resistance to endocrine therapy in patients with breast cancer. To test the hypothesis that inhibition of the EGFR signalling pathway affects the antitumour effect of end...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, S, Kurebayashi, J, Otsuki, T, Yamamoto, Y, Tanaka, K, Sonoo, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395342/
https://www.ncbi.nlm.nih.gov/pubmed/14710235
http://dx.doi.org/10.1038/sj.bjc.6601504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395342/
https://www.ncbi.nlm.nih.gov/pubmed/14710235
http://dx.doi.org/10.1038/sj.bjc.6601504

Ejemplares similares